Pharmaceutical Firms Are Cleaning House to Profit

Pharmaceutical Firms Are Cleaning House to Profit

There’s no doubt it was an unusually slow February in the healthcare M&A market. Historically, the middle of Q1 tends to dip and then rebound by March, but with less than 100 deals on the books, the rapid spread of the coronavirus, Covid-19, seems to have undercut investor confidence, both big and small. And although some biotech stocks have soared following announcements of their coronavirus treatment efforts, pharmaceutical firms have been relatively quiet. Aside from some players like Gilead (NASDAQ:GILD), which just announced a $4.9 billion acquisition of Forty Seven, Inc. (NASDAQ: FTSV) and whose product remdesivir is seen a hope as a potential treatment for Covid-19, no... Read More »